Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350272 · ClinicalTrials.gov registry record · Phase 2
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
A Phase 2 study of HIV Infections, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT00350272 is a Phase 2 study of HIV Infections that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 76 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00350272, a Phase 2 study of HIV Infections, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1. This Phase 2 study will enroll 60 HIV-1-naive participants to assess the efficacy and safety of elvucitabine compared to lamivudine in combination with tenofovir and efavirenz as measured by changes in the participant's HIV-ribonucleic acid (RNA) level and CD4 cell count. The study treatment will be 12 weeks of blinded study medication followed by an additional 84 weeks of open-label treatment if the participant's response to treatment meets certain endpoints. The pharmacokinetics of elvucitabine will also be assessed during the study.
Conditions Studied
Interventions
- DRUG Lamivudine
- DRUG Efavirenz
- DRUG Tenofovir
- DRUG Elvucitabine
Study Locations (20)
Florida
- Clinical Trial Site - Clearwater
- Clinical Trial Site - Fort Myers
- Clinical Trial Site - Miami
- Clinical Trial Site - Miami
- Clinical Trial Site - Orlando
- Clinical Trial Site - Tampa
- Clinical Trial Site - Tampa
- Clinical Trial Site - West Palm Beach
California
- Clinical Trial Site - Long Beach
- Clinical Trial Site - Los Angeles
Texas
- Clinical Trial Site - Austin
- Clinical Trial Site - Dallas
Arkansas
- Clinical Trial Site - Little Rock
District of Columbia
- Clinical Trial Site - Washington D.C.
Illinois
- Clinical Trial Site - Chicago
Kansas
- Clinical Trial Site - Wichita
Maryland
- Clinical Trial Site - Washington D.C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00350272
The ClinicalTrials.gov registry entry for NCT00350272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which Lamivudine is the first listed.
NCT00350272 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT00350272 about?
NCT00350272 is a clinical study titled "Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants". Elvucitabine, a novel nucleoside analog, is being studied as a treatment for participants with human immunodeficiency virus (HIV)-1. This Phase 2 study will enroll 60 HIV-1-naive participants to assess the efficacy and safety of elvucitabine compared to lamivudine in combination with tenofovir and e...
What is the current status of trial NCT00350272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2006-05. Estimated completion is 2009-04.
What conditions does trial NCT00350272 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00350272?
The interventions under investigation include: Lamivudine (DRUG), Efavirenz (DRUG), Tenofovir (DRUG), Elvucitabine (DRUG).
Who is sponsoring clinical trial NCT00350272?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350272 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.